PTGX
Protagonist Therapeutics, Inc.
Stock
$140.06+0.87 (+0.63%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $783M | $567M | $419M | $342M | $237M | $327M | $306M | $133M | $129M | $144M | $78M | $12M | $9.3M |
| Current assets | $807M | $578M | $592M | $356M | $243M | $341M | $316M | $145M | $138M | $151M | $83M | $14M | — |
| Total assets | $886M | $668M | $745M | $358M | $248M | $348M | $324M | $155M | $139M | $164M | $94M | $15M | — |
| Current liabilities | $37M | $45M | $47M | $21M | $31M | $44M | $40M | $35M | $26M | $43M | $6.4M | $3.1M | — |
| Long-term debt | — | — | — | — | — | — | — | $9.8M | — | — | — | — | — |
| Total liabilities | $44M | $53M | $69M | $21M | $32M | $48M | $45M | $75M | $27M | $43M | $6.4M | $5.2M | — |
| Shareholders' equity | $842M | $615M | $675M | $337M | $216M | $300M | $280M | $80M | $113M | $121M | $88M | −$27M | −$13M |
| Shares outstanding | 64.7M | 63.8M | 61.4M | 58.3M | 51.3M | 48.4M | 43.8M | 27.3M | 23.3M | 21.1M | 16.8M | — | — |
| Current ratio | 21.71 | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 | 4.10 | 5.26 | 3.55 | 12.94 | 4.54 | — |